<DOC>
	<DOCNO>NCT02098941</DOCNO>
	<brief_summary>The Objective study compare 2-year retention rate topiramate , levetiracetam oxcarbazepine long term epilepsy treatment .</brief_summary>
	<brief_title>Evaluate Retention Rate Topiramate , Levetiracetam Oxcarbazepine Long-term Epilepsy Treatment</brief_title>
	<detailed_description>Primary objective The Objective study compare 2-year retention rate topiramate , levetiracetam oxcarbazepine long term epilepsy treatment . Secondary objective The main secondary objective study evaluate confound factor associate retention rate topiramate compare anticonvulsant . 1 . Baseline characteristic - Seizure Type - Gender - Age onset 2 . Treatment regimen - Number concomitant medication - Type drug combination - Final target dose - Titration speed Other secondary objective The secondary objective study compare following medication : - Rate seizure reduction ( ≥75 % , ≥50 % ) - Rate seizure freedom</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subjects begin treatment topiramate , levetiracetam oxcarbazepine mono addon therapy conventional drug . Subjects partial generalize epilepsy Subjects administer combination therapy topiramate , levetiracetam oxcarbazepine Subjects past experience surgery epilepsy treatment Subjects follow least 1 year</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>topiramate</keyword>
	<keyword>oxcarbazepine</keyword>
	<keyword>levetiracetam</keyword>
	<keyword>retention rate</keyword>
</DOC>